New Insight: A Look at OPT-302/Sozinibercept with Megan Baldwin, PhD
Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and Managing Director of Opthea Limited, to discuss OPT-302 or sozinibercept, the company's novel anti-VEGF-C / VEGF-D treatment for wet AMD and other retinal diseases.
Episode Highlights:
0:06 Introduction
0:37 Background of Dr. Baldwin
9:56 Promising data on OPT-302/sozinibercept
16:39 Making decisions as a clinician, industry leader
22:11 Future of the treatment landscape
28:24 What’s next for Opthea?
32:39 Conclusion
Please direct any podcast-related inquiries to ciapoce@mjhlifesciences.com.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.